Sayers & Ors v Smithkline Beecham Plc & Ors [2004] EWHC 1899 (QB) (30 July 2004)

Sayers & Ors v Smithkline Beecham Plc & Ors [2004] EWHC 1899 (QB) (30 July 2004)

The court approved in principle the settlement terms offered by the defendants, finding that the claimants' prospects of restored public funding were remote and that the value of costs amnesties outweighed the limited rights being surrendered. Orders were made to ensure claimants clarify intentions, with discontinuance or dismissal subject to procedural safeguards and court approval where required. The group litigation status remains pending further developments, and cost-capping was refused absent compelling evidence.

Citation
[2004] EWHC 1899
Parties
Claimants: Paul Sayers and others; First Defendant: Smithkline Beecham Plc; Second Defendant: Smith Kline & French Laboratories Ltd.; Third Defendant: Merck & Co. Inc.; Fourth Defendant: Aventis Pasteur MSD Ltd.
Jurisdiction
England and Wales
Judgment Date
30 July 2004
Procedural Posture
Group Litigation (product Liability) / Case Management Conference; Orders on Discontinuance, Costs, and Settlement Approval
Outcome
Orders made for notification of intentions, discontinuance or continuation of claims, approval in principle of settlement terms, and directions for disclosure and future case management.
Legal Topics
Group Litigation, Discontinuance of Claims, Costs Orders, Legal Aid Withdrawal, Settlement Approval, Consumer Protection Act 1987, Disability and Litigation Friends
Civil Procedure Product Liability Medical Law Group Litigation Discontinuance of Claims Costs Orders Legal Aid Withdrawal Settlement Approval +2 more

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 6 Authorities cited 6 Party arguments 2 Amounts and remedies 8
Sign in to unlock

Parties

Paul Sayers and others

Claimants

Smithkline Beecham Plc

First Defendant

Smith Kline & French Laboratories Ltd.

Second Defendant

Merck & Co. Inc.

Third Defendant

Aventis Pasteur MSD Ltd.

Fourth Defendant

Procedural Posture

Group Litigation (product Liability) / Case Management Conference; Orders on Discontinuance, Costs, and Settlement Approval

Legal Issues

  1. 1 What orders should be made for claimants wishing to discontinue, proceed, or undecided in group litigation after withdrawal of public funding?
  2. 2 What is the effect of discontinuance on future claims and costs liability?
  3. 3 What is the court's role in approving settlements involving protected parties?

Ratio Decidendi

The court approved in principle the settlement terms offered by the defendants, finding that the claimants' prospects of restored public funding were remote and that the value of costs amnesties outweighed the limited rights being surrendered. Orders were made to ensure claimants clarify intentions, with discontinuance or dismissal subject to procedural safeguards and court approval where required. The group litigation status remains pending further developments, and cost-capping was refused absent compelling evidence.

Court Disposition

Orders made for notification of intentions, discontinuance or continuation of claims, approval in principle of settlement terms, and directions for disclosure and future case management.

Orders

  • Claimants who have not notified intentions must do so by 22 October 2004 or face dismissal of claims with costs up to discharge of legal aid certificate.
  • Claimants intending to discontinue must serve notice or agree terms by 22 October 2004 or notify intention to proceed.